Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study
Schizophrenia Research, 03/12/2012
Wang M et al. – Metformin was effective and safe in attenuating antipsychotic–induced weight gain and insulin resistance in first–episode schizophrenia patients. Patients displayed good adherence to metformin.
- Seventy-two patients with first-episode schizophrenia who gained more than 7% of their predrug weight were randomly assigned to receive 1000mg/d of metformin or placebo in addition to their ongoing treatment for 12weeks using a double-blind study design.
- The primary outcome was change in body weight.
- The secondary outcomes included changes in body mass index, fasting glucose and insulin, and insulin resistance index.
- Of the 72 patients who were randomly assigned, 66 (91.6%) completed treatments.
- The body weight, body mass index, fasting insulin and insulin resistance index decreased significantly in the metformin group, but increased in the placebo group during the 12-week follow-up period.
- Significantly more patients in the metformin group lost their baseline weight by more than 7%, which was the cutoff for clinically meaningful weight loss.
- Metformin was tolerated well by majority patients.